Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the …
Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) is investing $150 million to increase access to COVID-19 monoclonal antibody therapeutic treatments for patients in vulnerable communities …
Read More WASHINGTON, D.C. — The U.S. Food and Drug Administration this week issued guidance for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential …
Read More
COATESVILLE, PA — Brandywine Hospital – Tower Health is fortunate to have received doses of the recently approved COVID-19 drug bamlanivimab, a monoclonal antibody to treat individuals diagnosed with COVID-19.
Read More
WASHINGTON, D.C. — Acting Commissioner of Food and Drugs Janet Woodcock M.D. recently released a statement on the Food and Drug Administration’s work to support medical product development to address …
Read More
WASHINGTON, D.C. — A web-based COVID-19 outpatient treatment locator maintained by the U.S. Department of Health and Human Services (HHS) is now available to assist healthcare providers and patients in finding potential …
Read More
HARRISBURG, PA — Pennsylvania Treasurer Joe Torsella this week co-filed a shareholder proposal at Gilead, maker of remdesivir (brand name: Veklury), the only antiviral drug approved by the Food and …
Read MoreWASHINGTON, D.C. — The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate …
Read MoreWASHINGTON, D.C. — The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or …
Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services this week announced plans to allocate initial doses of Eli Lilly and Company’s investigational monoclonal antibody therapeutic, bamlanivimab, which …
Read More